No profile data available.
iBio, Inc. (IBIO) is a healthcare company in the medication development research industry, based in San Diego, United States, with about 23 full-time employees.
It reported revenue of $100,000 for fiscal year 2026, down 75.0% from fiscal year 2025, and net income of -$33.04 million. Its market capitalization was $43.27 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2026; market data as of October 9, 2026.
, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
iBio reported $100,000 in revenue for fiscal year 2026, down 75.0% from $400,000 in fiscal year 2025.
$43.27 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include Insight Molecular Diagnostics Inc. (IMDX), MindWalk Holdings Corp. (HYFT), Caribou Biosciences, Inc. (CRBU), Ernexa Therapeutics Inc. (ERNA).